Lecithinized superoxide dismutase in the past and in the present: Any role in the actual pandemia of COVID-19?
Study Goal
The researchers aimed to evaluate the potential of lecitinized superoxide dismutase (PC-SOD) as a therapy for COVID-19 by examining its role in reducing oxidative stress and modulating immune response.
Results Summary
The abstract suggests that PC-SOD has potential due to its bioavailability, safety, and modulatory effects on innate immune response, but emphasizes the need for clinical trials to confirm its efficacy in treating COVID-19.
Population
Animal and human studies (specific population not detailed).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
antioxidants | decrease | the amplification of inflammation | - | - | a potential therapy | #1 |
lecitinized superoxide dismutase (PC-SOD) | neutral | innate immune response | - | - | modulatory effect | #2 |
lecitinized superoxide dismutase (PC-SOD) | decrease | harmful consequences of oxidative stress | - | - | reducing | #3 |
The Coronavirus disease 19 (Covid-19) pandemic is devastating the public health: it is urgent to find a viable therapy to reduce the multiorgan damage of the disease. A validated therapeutic protocol is still missing. The most severe forms of the disease are related to an exaggerated inflammatory response. The pivotal role of reactive oxygen species (ROS) in the amplification of inflammation makes the antioxidants a potential therapy, but clinical trials are needed. The lecitinized superoxide dismutase (PC-SOD) could represent a possibility because of bioaviability, safety, and its modulatory effect on the innate immune response in reducing the harmful consequences of oxidative stress. In this review we summarize the evidence on lecitinized superoxide dismutase in animal and human studies, to highlight the rationale for using the PC-SOD to treat COVID-19.